Lymphocyte inhibition by hla peptides

Details Lymphocyte inhibition by hla peptides Lymphocyte inhibition by hla peptides

C - Chemistry, Metallurgy

07

K

167/205, 530/7.0

C07K 7/08 (2006.01) A61K 38/00 (2006.01) A61K 38/08 (2006.01) A61K 38/10 (2006.01) A61K 38/16 (2006.01) C07K 7/06 (2006.01) C07K 14/00 (2006.01) C12Q 1/04 (2006.01) G01N 33/566 (2006.01) G01N 33/68 (2006.01)

Patent

CA 1339185

Novel peptides are provided for modulating the cytotoxic effect of CTL's. Novel peptides cross reactive with the C-terminal or N-terminal portions of the .alpha., or .alpha.2 domains, respectively, of the MHC antigen providing the CTL restriction are employed for CTL modulation. The peptides may be used in vivo or in vitro for controlling cellular lysis.

557873

Affiliated with

Also associated with

Rating

Lymphocyte inhibition by hla peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lymphocyte inhibition by hla peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphocyte inhibition by hla peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1224928